Additional Study Information: The purpose of this study is to test the safety and effectiveness of the study drug, BI 1387446, given alone or combined with the study drug, BI 754091, in subjects with different types of advanced cancer. BI 1387446 will be injected directly into at least one tumor site. BI 754091 will be given by intravenous (IV) infusion, which is a slow injection of the study drug directly into a vein. Both of these drugs are immunotherapy drugs. The researchers hope that these drugs will activate a person's immune system to work against their cancer. BI 1387446 given alone and in combination with BI 754091 has been tested in animals but not yet in people. Cancers include: Bladder cancer, breast cancer, ovarian cancer, kidney/adrenal cancer, liver cancer, lung cancer, melanoma, and prostate cancer.